Pharmaceutical Executive June 30, 2025
Mike Hollan

Customers will be able to access prescription services through the NovoCare Pharmacy.

Novo Nordisk continues its efforts to promote the use of genuine, FDA approved GLP-1s while combatting the use of compounded alternatives.

This has been a uniquely difficult issue in the weight-loss drug space. When Novo’s Wegovy and Ozempic hit the market several years ago, the drugs became very popular very quickly. This resulted in shortages, which forced people to search out alternatives. While the official drugs were still in short supply, FDA briefly relaxed its regulations on compounded medications.

Who is Novo Nordisk partnering with?

However, the supply has since stabilized, and FDA is enforcing a ban on compounding these medications. Novo Nordisk is active in taking...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Partnerships, Pharma / Biotech, Trends
What’s new with GLP-1s
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Medicare Is Covering GLP-1s – It’s Time to Cover the Care That Makes Them Sustainable

Share Article